{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:18:39Z","timestamp":1788279519755,"version":"build-2803163510"},"reference-count":45,"publisher":"American Chemical Society (ACS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccbyncnd_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI115940"],"award-info":[{"award-number":["U01AI115940"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tuberculosis is the leading cause of death from a single infectious agent, ranking above the human immunodeficiency virus (HIV). Effective treatment using antibiotics is achievable, but poor patient compliance constitutes a major challenge impeding successful pharmacotherapeutic outcomes. This is often due to the prolonged treatment periods required and contributes significantly to the rising incidence of drug resistance, which is a major cause of tuberculosis mortality. Thus, innovative interventions capable of encouraging compliance and decreasing lengthy and frequent dosing are needed. Previously, aqueous tin protoporphyrin IX (SnPPIX), a heme oxygenase-1 inhibitor, administered as multiple daily intraperitoneal (IP) injections, showed considerable antitubercular efficacy and treatment shortening capabilities as a host-directed therapy in infected mice. Since daily IP injection is a clinically impractical administration approach, this proof-of-concept study aims to develop a novel, sustained action injectable formulation of SnPPIX for safe intramuscular (IM) administration. Herein, a SnPPIX-loaded poloxamer-poly(acrylic acid)-based thermoresponsive injectable formulation (SnPPIX-TIF) is designed for effective IM delivery. Results show SnPPIX-TIF is microparticulate, syringeable, injectable, and exhibits complete in vitro\/in vivo gelation. Administered once weekly, SnPPIX-TIF significantly prolonged absorption and antimicrobial efficacy in infected mice. In addition, SnPPIX-TIF is well-tolerated in vivo; results from treated animals show no significant histopathologic alterations and were indistinguishable from the untreated control group, thus supporting its biocompatibility and preclinical safety. Overall, the IM delivery of the thermoresponsive injectable formulation safely sustains antitubercular effect in an infected murine model and decreases the number of injections required, signifying a potentially practical approach for future clinical translation.<\/jats:p>","DOI":"10.1021\/acsptsci.0c00185","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T11:01:58Z","timestamp":1608289318000},"page":"276-287","source":"Crossref","is-referenced-by-count":5,"title":["A Long-Acting Thermoresponsive Injectable Formulation\nof Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine\nInfection Model"],"prefix":"10.1021","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0880-3997","authenticated-orcid":true,"given":"Oluwatoyin A.","family":"Adeleke","sequence":"first","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services , , , ,","place":["Bethesda, Maryland, United States, 20892"]},{"name":"Sefako Makgatho Health Science University , , ,","place":["Pretoria, South Africa, 0208"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Fisher","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services , , , ,","place":["Bethesda, Maryland, United States, 20892"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Moore","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services , , , ,","place":["Rockville, Maryland, United States, 20852"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn A.","family":"Nardone","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services , , , ,","place":["Rockville, Maryland, United States, 20852"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Sher","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services , , , ,","place":["Bethesda, Maryland, United States, 20892"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"issue":"3","key":"2026090111334215100_cit1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1128\/CMR.16.3.463-496.2003","article-title":"Mycobacterium\ntuberculosis pathogenesis and molecular determinants of virulence","volume":"16","author":"Smith","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"2026090111334215100_cit2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/403623","article-title":"Tuberculosis: new\naspects of an old disease","volume":"2011","author":"Jordao","year":"2011","journal-title":"Int. J. Cell Biol."},{"issue":"1","key":"2026090111334215100_cit3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thorsurg.2018.09.002","article-title":"History\nof Pulmonary Tuberculosis","volume":"29","author":"Pezzella","year":"2019","journal-title":"Thoracic Surgery\nClinics"},{"key":"2026090111334215100_cit4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijpharm.2019.05.061","article-title":"Solidified\nSNEDDS for the oral delivery\nof rifampicin: Evaluation, proof of concept, in vivo kinetics, and\nin silico GastroPlusTM simulation","volume":"566","author":"Hussain","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"6","key":"2026090111334215100_cit5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/14737167.2018.1507821","article-title":"Bedaquiline-versus\ninjectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness\nanalysis","volume":"18","author":"Ionescu","year":"2018","journal-title":"Expert Review of Pharmacoeconomics\nand Outcomes Research"},{"key":"2026090111334215100_cit6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.15585\/mmwr.mm6911a2","article-title":"Global epidemiology\nof tuberculosis and progress toward meeting global\ntargets \u2500 Worldwide, 2018","volume":"69","author":"MacNeil","year":"2020","journal-title":"Morbidity\nand Mortality Weekly Report"},{"key":"2026090111334215100_cit7","unstructured":"World Health Organization (WHO).\n          .  Global Tuberculosis Report (2020). Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/336069\/9789240013131-eng.pdf?ua=1 (accessed Oct. 28, 2020)."},{"key":"2026090111334215100_cit8","unstructured":"TB Alliance (2019). Available via the Internet\nat: https:\/\/www.tballiance.org\/why-new-tb-drugs\/global-pandemic (accessed Oct. 2, 2020)."},{"issue":"1\u20132","key":"2026090111334215100_cit9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ijpharm.2018.06.004","article-title":"Isoniazid-loaded\norodispersible strips: Methodical design, optimization and in vitro-in\nsilico characterization","volume":"547","author":"Adeleke","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"483","key":"2026090111334215100_cit10","doi-asserted-by":"publisher","first-page":"eaau6267","DOI":"10.1126\/scitranslmed.aau6267","article-title":"A gastric resident drug\ndelivery system for prolonged gram-level dosing of tuberculosis treatment","volume":"11","author":"Verma","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"2026090111334215100_cit11","unstructured":"World Health Organization.\n          .  Treatment of Tuberculosis:\nGuidelines\u25004th\nEdition (2010). Available via the Internet at: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44165\/9789241547833_eng.pdf (accessed Oct. 13, 2020)."},{"issue":"5","key":"2026090111334215100_cit12","doi-asserted-by":"publisher","first-page":"CD003343","DOI":"10.1002\/14651858.CD003343.pub4","article-title":"Directly observed therapy\nfor treating tuberculosis","author":"Karumbi","year":"2015","journal-title":"Cochrane Database\nSyst. Rev."},{"issue":"11","key":"2026090111334215100_cit13","doi-asserted-by":"publisher","first-page":"e14014","DOI":"10.1371\/journal.pone.0014014","article-title":"Patients\u2019\ncosts and cost-effectiveness\nof tuberculosis treatment in DOTS and non-DOTS facilities in Rio de\nJaneiro, Brazil","volume":"5","author":"Steffen","year":"2010","journal-title":"PLoS One"},{"key":"2026090111334215100_cit14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fmed.2017.00171","article-title":"Host-directed therapeutic\nstrategies for tuberculosis","volume":"4","author":"Kolloli","year":"2017","journal-title":"Front. Med."},{"issue":"11","key":"2026090111334215100_cit15","doi-asserted-by":"publisher","first-page":"CD006594","DOI":"10.1002\/14651858.CD006594.pub3","article-title":"Reminder systems\nto improve patient adherence to tuberculosis\nclinic appointments for diagnosis and treatment","author":"Liu","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"2026090111334215100_cit16","doi-asserted-by":"publisher","first-page":"CD007952","DOI":"10.1002\/14651858.CD007952.pub3","article-title":"Incentives\nand enablers to improve adherence in tuberculosis","author":"Lutge","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"2026090111334215100_cit17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0970-2113.197118","article-title":"Rapid diagnosis\nand shorter regimen\nfor multidrug-resistant tuberculosis: A priority to improve treatment\noutcome","volume":"34","author":"Prasad","year":"2017","journal-title":"Lung India: Off. Organ Indian Ches\nSoc."},{"issue":"4","key":"2026090111334215100_cit18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nri3813","article-title":"Advancing host-directed therapy for\ntuberculosis","volume":"15","author":"Wallis","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"2026090111334215100_cit19","doi-asserted-by":"publisher","first-page":"e01675-16","DOI":"10.1128\/mBio.01675-16","article-title":"Pharmacological inhibition of host\nheme oxygenase-1 suppresses Mycobacterium tuberculosis infection in\nvivo by a mechanism dependent on T lymphocytes","volume":"7","author":"Costa","year":"2016","journal-title":"mBio"},{"key":"2026090111334215100_cit20","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/infdis\/jiz517","article-title":"Adjunctive host-directed therapy\nwith statins improves tuberculosis-related outcomes in mice","volume":"221","author":"Dutta","year":"2020","journal-title":"J. Infect. Dis."},{"key":"2026090111334215100_cit21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","article-title":"Therapeutic host-directed strategies\nto improve outcome in tuberculosis","volume":"13","author":"Young","year":"2020","journal-title":"Mucosal\nImmunol."},{"key":"2026090111334215100_cit22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lfs.2018.05.011","article-title":"Heme oxygenase-1\ninhibitor tin-protoporphyrin\nimproves liver regeneration after partial hepatectomy","volume":"204","author":"Pibiri","year":"2018","journal-title":"Life Sci."},{"key":"2026090111334215100_cit23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trsl.2018.12.008","article-title":"Enhancing responsiveness\nof pancreatic cancer cells to gemcitabine\ntreatment under hypoxia by heme oxygenase-1 inhibition","volume":"207","author":"Abdalla","year":"2019","journal-title":"Translational Research"},{"issue":"3","key":"2026090111334215100_cit24","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3892\/mmr.2019.9811","article-title":"Standardized microwave\nextract of Sappan Lignum exerts anti-inflammatory effects through\ninhibition of NF-\u03baB activation via regulation of heme oxygenase-1\nexpression","volume":"19","author":"Chowdhury","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"5","key":"2026090111334215100_cit25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216405","article-title":"Heme oxygenase-1-Dependent\nanti-inflammatory effects of atorvastatin in zymosan-injected subcutaneous\nair pouch in mice","volume":"14","author":"El-Achkar","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"2026090111334215100_cit26","first-page":"600","article-title":"Administration\nof substances to laboratory animals: routes of administration and\nfactors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J. Am. Assoc. Lab. Animal\nSci."},{"issue":"1","key":"2026090111334215100_cit27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","article-title":"Intraperitoneal\nRoute of Drug Administration: Should it Be Used in Experimental Animal\nStudies?","volume":"37","author":"Al Shoyaib","year":"2020","journal-title":"Pharm. Res."},{"issue":"10","key":"2026090111334215100_cit28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186018","article-title":"Pharmacokinetics\nand toxicity of\nsubcutaneous administration of carboplatin in poloxamer 407 in a rodent\nmodel pilot study","volume":"12","author":"Risselada","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"2026090111334215100_cit29","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.3762\/bjnano.10.222","article-title":"Design of a nanostructured mucoadhesive system containing\ncurcumin for buccal application: from physicochemical to biological\naspects","volume":"10","author":"de Souza Ferreira","year":"2019","journal-title":"Beilstein J. Nanotechnol."},{"key":"2026090111334215100_cit30","doi-asserted-by":"publisher","first-page":"118924","DOI":"10.1016\/j.ijpharm.2019.118924","article-title":"Poloxamer 407 based-nanoparticles for controlled release\nof methotrexate","volume":"575","author":"Moura","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"12","key":"2026090111334215100_cit31","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/pharmaceutics11120671","article-title":"Poloxamer Hydrogels\nfor Biomedical Applications","volume":"11","author":"Russo","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"2026090111334215100_cit32","doi-asserted-by":"publisher","first-page":"16105","DOI":"10.1038\/s41598-019-52645-0","article-title":"Surface stabilized\natorvastatin nanocrystals with improved bioavailability\nsafety and antihyperlipidemic potential","volume":"9","author":"Sharma","year":"2019","journal-title":"Sci.\nRep."},{"issue":"4","key":"2026090111334215100_cit33","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/polym3041972","article-title":"Water soluble polymers\nfor pharmaceutical applications","volume":"3","author":"Kadajji","year":"2011","journal-title":"Polymers"},{"issue":"5","key":"2026090111334215100_cit34","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1208\/s12249-018-1010-7","article-title":"Thermosensitive\nPoloxamer 407\/poly (acrylic acid) hydrogels with potential application\nas injectable drug delivery system","volume":"19","author":"Boonlai","year":"2018","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"2026090111334215100_cit35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jbm.820060609","article-title":"Artificial\nskin I. Preparation and properties of pluronic F-127 gels for treatment\nof burns","volume":"6","author":"Schmolka","year":"1972","journal-title":"J. Biomed. Mater. Res."},{"issue":"2","key":"2026090111334215100_cit36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejpb.2013.09.008","article-title":"The clinical\nefficacy of cosmeceutical\napplication of liquid crystalline nanostructured dispersions of alpha\nlipoic acid as anti-wrinkle","volume":"86","author":"Sherif","year":"2014","journal-title":"Eur. J. Pharm.\nBiopharm."},{"key":"2026090111334215100_cit37","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/jbm.b.34524","article-title":"The characteristics\nof mussel-inspired nHA\/OSA injectable hydrogel and repaired bone defect\nin rabbit","volume":"108","author":"Liu","year":"2020","journal-title":"J. Biomed. Mater. Res., Part B"},{"issue":"4","key":"2026090111334215100_cit38","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1208\/s12249-018-0963-x","article-title":"Delivery Considerations\nof Highly\nViscous Polymeric Fluids Mimicking Concentrated Biopharmaceuticals:\nAssessment of Injectability via Measurement of Total\nWork Done \u201cWT\u201d","volume":"19","author":"Zhang","year":"2018","journal-title":"AAPS\nPharmSciTech"},{"key":"2026090111334215100_cit39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ijpharm.2018.11.012","article-title":"Injectability as\na function of viscosity\nand dosing materials for subcutaneous administration","volume":"554","author":"Watt","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"2","key":"2026090111334215100_cit40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1208\/s12249-011-9625-y","article-title":"Injectability\nevaluation: an open\nissue","volume":"12","author":"Cilurzo","year":"2011","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"2026090111334215100_cit41","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/polym11111801","article-title":"Bioadhesive Matrix\nTablets Loaded with Lipophilic Nanoparticles as Vehicles for Drugs\nfor Periodontitis Treatment: Development and Characterization","volume":"11","author":"Murgia","year":"2019","journal-title":"Polymers"},{"key":"2026090111334215100_cit42","doi-asserted-by":"publisher","first-page":"118705","DOI":"10.1016\/j.ijpharm.2019.118705","article-title":"Development, characterization and\npharmacokinetics of mupirocin-loaded nanostructured lipid carriers\n(NLCs) for intravascular administration","volume":"571","author":"Alcantara","year":"2019","journal-title":"Int.\nJ. Pharm."},{"issue":"1","key":"2026090111334215100_cit43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1208\/s12249-012-9920-2","article-title":"Development and\nvalidation of a discriminative dissolution test for betamethasone\nsodium phosphate and betamethasone dipropionate intramuscular injectable\nsuspension","volume":"14","author":"Simon","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"2026090111334215100_cit44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.addr.2018.06.009","article-title":"Practical\nguidelines for the characterization and quality control of pure drug\nnanoparticles and nano-cocrystals in the pharmaceutical industry","volume":"131","author":"Peltonen","year":"2018","journal-title":"Adv. Drug Delivery Rev."},{"issue":"7","key":"2026090111334215100_cit45","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/pharmaceutics12070674","article-title":"Formulation\nof Sustained Release Hydrophilic Matrix Tablets of Tolcapone with\nthe Application of Sedem Diagram: Influence of Tolcapone\u2019s\nParticle Size on Sustained Release","volume":"12","author":"Nardi-Ricart","year":"2020","journal-title":"Pharmaceutics"}],"container-title":["ACS Pharmacology &amp; Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsptsci.0c00185","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article-pdf\/4\/1\/276\/67463955\/acsptsci.0c00185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article-pdf\/4\/1\/276\/67463955\/acsptsci.0c00185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:33:51Z","timestamp":1788276831000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article\/4\/1\/276\/1464994\/A-Long-Acting-Thermoresponsive-Injectable"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,18]]},"published-print":{"date-parts":[[2021,2,12]]}},"URL":"https:\/\/doi.org\/10.1021\/acsptsci.0c00185","relation":{},"ISSN":["2575-9108"],"issn-type":[{"value":"2575-9108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]}}}